Unexpectedly, the protein-tyrosine kinase inhibitor imatinib, inhibiting BCR-ABL, which can induce constitutive active downstream targets of oncogenic RAS (Cilloni and Saglio, 2012), failed to rescue both the KRASG12V leukemia model adult-stage mortality (Fig. S3) and the reduced phagocytic activity of KRASG12V hemocytes (Fig. 6B-E). Here, ABL1 is linked to leukemia.